ESR1 and breast carcinoma: Consequently, ferrocene-containing Tamoxifen analogues display cytotoxicity not only on Estrogen Receptor positive (ER+) breast cancer cells, but also on ER-independent cell lines, due to the ROS-generating ability of the organometallic agents playing a predominant role in their activity [7].